Skip to main content

Table 2 Recent clinical trials studying regional nodal irradiation in breast cancer

From: Current controversies in radiotherapy for breast cancer

 

MA.20 [10]

EORTC 22922/10925 [9]

DBCG-IMN [35]

French trial [36]

Study design

Phase III randomized controlled trial

Phase III randomized controlled trial

Prospective cohort study

Phase III randomized controlled trial

Treatment arms

WBI + boost

WBI + boost + SCV/IMN

WBI + Boost TWI

WBI + boost + SCV/IMN TWI + SCV/IMN

WBI + Boost + SCV (left sided tumor location)

WBI + Boost + SCV/IMN (right sided tumor location)

TWI + SCV

TWI + SCV/IMN

Inclusion criteria

N+ or N0 high risk (T3 or T2 with < 10 lymph resected lymph nodes and additional risk factors present)

N+ or N0 (medial or central tumor location)

N+

N+ or N0 (medial or central tumor location)

Number of patients

1832

4004

3089

1334

Recruitment period

2000–2007

1996–2004

2003–2007

1991–1997

Median follow up

9.5 years

10.9 years

8.9 years

8.6 years

Disease-free survival

77.0%

82.0%

69.1%

72.1%

n.s.

49.9%

53.2%

p = 0.01; HR 0.76 (95% CI 0.61–0.94)

p = 0.04; HR 0.89

(95% CI 0.80–1.00)

p = 0.35

Overall survival

81.8%

82.8%

80.7%

82.3%

72.2%

75.9%

59.3%

62.6%

p = 0.38; HR 0.91 (95%-CI 0.72–1.13)

p = 0.06; HR 0.87 (95%-CI 0.76–1.00)

p = 0.005; HR 0.82 (95%–CI 0.72–0.94)

p = 0.8

  1. WBI whole-breast irradiation, TWI thoracic wall irradiation, SCV supra-/infraclavicular region, IMN internal mammary lymph nodes, HR hazard ratio, CI confidence interval